Advanced image analysis firm QUIBIM has launched a new MR spectroscopy analysis tool that will help oncologists diagnose and treat brain gliomas.
The tool quantifies the metabolite 2-hydroxyglutarate because its levels help clinicians predict whether patients have low-grade brain gliomas, the company said. It does this by analyzing MR spectroscopy images and producing a report that graphs the analysis.
The new tool is available in QUIBIM's Precision Platform software package, according to the firm.